Abstract:Objective To investigate the value of intravoxel incoherent motion (IVIM) imaging in noninvasive judgement of isocitrate dehydrogenase 1 (IDH1) gene status of diffuse glioblastoma.Methods A total of 95 patients with diffuse glioma were enrolled in this prospective study.The IVIM imaging parameters of the real area of tumors,including perfusion proportion coefficient (F),average apparent diffusion coefficient (ADCmean),fast apparent diffusion coefficient (fastADC),diffusion coefficient (DDC),and pseudo-diffusion coefficient (D *) were measured.The standardized parameters of the contralateral white matter area including relative perfusion proportion coefficient (nrF),relative apparent diffusion coefficient (nrADCmean),relative diffusion coefficient (nrfastADC),relative diffusion coefficient (nrDDC),and relative pseudodiffusion coefficient (nrD *) were calculated.All patients were followed up for pathological diagnosis and IDH1 gene test results.The independent-samples t test was used to analyze the differences between the wild type and mutant type parameters of IDH1 gene.The effective parameters were used to plot the receiver operating characteristics (ROC) curve.The correct predictive rate of IDH1 gene was calculated by Logistic regression analysis.Results The values of F,ADCmean,nrADCmean and DDC in mutant-type low-level group were significantly higher than those in wild-type low-level group (all P ＜ 0.05).But there were no significant differences.in the nrF,D *,nrD *,nrDDC,fastADC,or nrfastADC between the two groups (all P＞0.05).The F value and fastADC in mutant-type high-level group were significantly lower than those in wild-type high-level group (both P ＜ 0.05).But there were no significant differences in the nrF,ADCmean,nrADCmean,D *,nrD *,DDC,nrDDC or nrfastADC between the two groups (all P＞0.05).In low-level glioma patients,the cut-off value,sensitivity,specificity and ROC area under curve (AUC) of F value were 0.125,0.667,0.625 and 0.780,respectively;ADCmean were 1.182,0.750,0.875 and 0.842,respectively;nrADCmean were 1.481,0.762,0.875 and 0.899,respectively;and DDC were 1.193,0.792,0.750 and 0.774.In high-level glioma patients,the cut-off value,sensitivity,specificity and ROC area under curve (AUC) of F value were 0.155,0.750,0.750 and 0.775,respectively;and fastADC were 1.545,0.708,0.875 and 0.813,respectively.Low-grade glioma combined with F and nrADCmean concluded that the correct predictive rate of IDH1 gene was 93.8％ and the likelihood ratio was 13.97.High-grade glioma combined with F and fastADC concluded that the correct predictive rate of IDH 1 gene was 82.5％ and the likelihood ratio was 46.07.Conclusion IVIM examination provides a new method for noninvasive diagnosis of IDH1 gene status in glioblastoma before surgery.

Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation

Predicting IDH mutation status as well as Ki-67 and p53 expression in high-grade gliomas using amide proton transfer-weighted and arterial spin labeling MRI

Noninvasive Idh1 Mutation Estimation Based on A Quantitative Radiomics Approach for Grade Ii Glioma

Rapid Diagnosis of IDH1-mutated Gliomas by 2-HG Detection with Gas Chromatography Mass Spectrometry.

Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning

Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI

Investigation on Glioma Using FT-mid-IR Spectroscopy

Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid

Predicting Isocitrate Dehydrogenase Status in Non-Contrast-Enhanced Adult-Type Astrocytic Tumors Using Diffusion Tensor Imaging and 11C-Methionine, 11C-Choline, and 18F-Fluorodeoxyglucose PET

Insight into deep learning for glioma IDH medical image analysis: A systematic review

Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas

Biom-72. Integration Of Ultrasensitive Electroluminescent Immunoassay And Cell-Free Dnamethylation Analysis For Non-Invasive Monitoring Of Adult Diffuse Gliomas

Beyond T2-FLAIR mismatch sign in isocitrate dehydrogenase mutant 1p19q non-codeleted astrocytoma: Analysis of tumor core and evolution with multiparametric magnetic resonance imaging

Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.

Path-39. Ai-Based Identification Of Glioma Idh Mutational Status From H&E-Stained Whole Slide Images

A preliminary study on noninvasive prediction of isocitrate dehydrogenase 1 gene status in glioblastoma by intravoxel incoherent motion imaging

Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas

Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma

Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion‐weighted MRI models

Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas